

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
S403
Objective
To evaluate the prevalence of residual symptoms (both
depressive and manic) in euthymic patients with bipolar disorder
and seek for associated factors.
Methodology
A total of 30 patients with bipolar disorder were
enrolled for this study. They were in remission for at least two
months. The patients answered the Hamilton Depression Rating
Scale and the Disorder Questionnaire Mood Hirschfeld (the MDQ
scale).
Results
The average age of our patients was 43
±
13 years.
Most patients were from a rural area (70%), married (60%) and did
not go beyond secondary school level (93.3%).
Forty percent (40%) had organic personal history.
Social dysfunction was found in 40% of cases, and professional dif-
ficulties in 30% of patients.
Depressive residual symptoms were found in 33.3% in cases and
hypomaniac ones in 26.6%.
Residual depressive symptoms were significantly more frequent
among married patients and having organic personal history
(
P
= 0.025).
The professional difficulties were associated with male gender
(
P
= 0.025) and the poor quality of free interval (
P
= 0.03).
Conclusion
These results illustrate that the “intercritical phase”
in bipolar disorder is not really euthymic. These findings are
in favour of developing interventions to manage subthreshold
symptoms to reduce their impact on social and professional
functioning.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.1151EV167
Evolution of inflammatory
dysregulation and oxidative stress in
patients with first episode of mania
S. García
1 , 2 ,∗
, P . López Pe˜na
1 , 2 , I. Zorrilla
1 , A.García-Alocen
1 ,M. Martínez-Cengotitabengoa
1 , 3 , 4 , C . Bermúdez-Ampudia
1 ,K.S. Mac-Dowell
5 , 6 , S . Rodríguez
5 , J.C. Leza
5 , 6 ,A. González-Pinto
1 , 2 , 41
University Hospital of Araba Santiago, Psychiatry, Vitoria-Gasteiz,
Spain
2
University of the Basque Country, neuroscience, Bizkaia, Spain
3
National Distance Education University UNED, Associated Center of
Vitora, Vitoria, Spain
4
Biomedical Research Centre in Mental Health Network CIBERSAM,
Psychiatry, University Hospital of Araba, Vitoria, Spain
5
Faculty of Medicine, Complutense University and Health Research
Institute-IIS-12 de Octubre Hospital i + 12, Pharmacology, Madrid,
Spain
6
Biomedical Research Centre in Mental Health Network CIBERSAM,
Pharmacology, Faculty of Medicine, Complutense University, Madrid,
Spain
∗
Corresponding author.
Introduction
Recent studies have focused on the imbalance in
inflammatory and antioxidant pathways as possible causes of the
underlying neurodegenerative processes in bipolar disorder. Thus,
the study of these pathways in first episodes of mania (FEM) can
increase knowledge about this issue.
Aim
To compare plasma concentrations of pro-inflammatory
(MCP-1, PGE2, TNF ) and oxidative parameters (TAS, NO
2
and
TBARS) between controls and FEM patients and to analyze the evo-
lution of these parameters in patients from baseline to 6 months
assessment time.
Methods
This study included 44 FEMpatients and 79healthy con-
trols, aged 18 to 40. Blood samples were available for controls at
baseline and for patients at baseline and 6 months after. TAS and
TBARS were measured using non-EIA assay kits, N0
2
was measured
with Griess method and PGE2, MCP-1 and TNF with ELISA kits.
Results
At baseline, TAS was significantly lower in patients than
in controls and TBARS, MCP-1 and TNF were significantly higher
in patients. Among patients, TAS andMCP1 were lower at 6 months
than at the illness onset and PGE2 andNO
2
were significantly higher
than at baseline.
Conclusion
Patients presented an increased oxidative damage
and also a higher activation of pro-inflammatory pathways than
healthy controls at baseline. After 6 months their level of oxidative
stress continue increased. Pro-inflammatory parameters decreased
overtime (MCP-1 and TNF ) but PGE2, increased surprisingly. This
can be due to the fact that antipsychotics are not able to completely
reverse baseline inflammation.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.1152EV168
Treatment of bipolar patients in
manic phase: A comparison between
asenapine and aripiprazole
L. Girardi
∗
, S. Gili , E. Gambaro , E. Di Tullio , E. Gattoni ,
E. Grossini , S. Farruggio , L. Mora , C. Gramaglia , P. Zeppegno
Università del Piemonte Orientale, Translational Medicine, Novara,
Italy
∗
Corresponding author.
Introduction
Agitation is the most evident symptom in an acute
manic episode. It can be defined as excessive motor or verbal
activity that can degenerate into aggressive behaviour. Both arip-
iprazole and asenapine are indicated for the treatment of agitation
in patients with manic episode.
Aims
To retrospectively evaluate the acute effects of drug ther-
apy on psychomotor agitation rated with the PANSS-EC, the change
in manic symptoms through the YMRS, the QoL with the SF-36v2
and the cardiometabolic effects of the new oral APS.
Methods
We administered the following tests to 13 patients with
DBI at T0 (baseline), T1 (after 1 week), T2 (after 4 weeks), T3 (after
12 weeks) and T4 (after 24 weeks): PANSS-EC, YMRS, SF-36v2, CGI-
BD, CGI-S, HAM-D, BPRS. We also considered weight, height, BMI,
ECG and complete blood count.
Results
Patients recruitment and statistical analyses are still in
progress. Our preliminary results suggest that there is not amarked
difference between the two drugs. We highlighted that there has
been a noticeable decrease in results at PANSS as well as at YMRS
from T0 to T4 and patients showed an improvement in QoL. Only
one patient treated with asenapine showed an increase in the
results of HAM-D.
Conclusions
Results suggest the efficacy of the two new APS but
further recruitment and data collection are needed to better under-
stand their impact on agitation and QoL, including the metabolic
profile, with the aim to help clinicians to make a more accurate
choice of drug for each specific patient.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.1153EV169
Depot aripiprazole as maintenance
treatment in bipolar disorder: Report
of a case
C. Gómez Sánchez-Lafuente
1 ,∗
,
R. Reina Gonzalez (General Practitioner)
2, A. De Severac Cano
1,
I. Tilves Santiago
1, F. Moreno De Lara
1, E. Mateos Carrasco
11
Hospital Universitario Virgen de la Victoria, Psychiatry, Málaga,
Spain
2
Hospital General Regional Universitario, Málaga, Spain
∗
Corresponding author.